Tirzepatide

Tirzepatide is a dual GLP-1/GIP receptor agonist that represents the next generation of weight loss medications. By targeting both GLP-1 and GIP receptors, it offers enhanced weight loss and metabolic benefits compared to single-target therapies.

Start with 2.5mg weekly and increase by 2.5mg every 4 weeks as tolerated. Maximum dose is 15mg weekly.

Superior weight loss compared to semaglutide, improved insulin sensitivity, better glucose control, and enhanced metabolic health.

Similar to semaglutide: nausea, vomiting, diarrhea, and potential pancreatitis. Requires medical supervision.